[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Institute of Dermatology, Thailand\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":74},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100626305","efficacy-of-an-antioxidant-moisturizing-serum-for-mild-to-moderate-seborrheic-dermatitis-100626305",false,"NCT07433907","Efficacy of an Antioxidant Moisturizing Serum for Mild to Moderate Seborrheic Dermatitis","A Prospective, Randomized, Split-Face Pilot Study Comparing the Efficacy of the Institute of Dermatology's Antioxidant Moisturizing Serum in Mild to Moderate Seborrheic Dermatitis","Pilot RCT","Inclusion Criteria\n\n* Age: ≥ 18 years old\n* Gender: Male and Female\n* Patient who never uses or has stopped using topical corticosteroids\u002Fcalcineurin inhibitor or other topical treatments exerting anti-inflammatory action (on the face) more than 2 weeks before entering this clinical trials.\n* Patient who does not use cosmetic containing any oxidants or others that exert anti-oxidant effect(s). If there is any, one must refrain from using them more than 2 weeks before entering this clinical trials.\n\nExclusion Criteria\n\n* Patients with known cases of underlying HIV\u002FAIDS, neurological condition e.g., Parkinson's disease.\n* Patient associated with any autoimmune diseases and other skin diseases\n* Patient takes any forms of oral immunotherapy more than 2 months up to the first day of clinical trials.\n* Patients continuously use of topical corticosteroids or other anti-inflammatory medicines on regular basis up to the first day of clinical trial.\n* Patient who refuses to stop using cosmetic(s) containing anti-oxidants or those exert anti-oxidant effect(s).\n* Patient who is allergic to the test product or one of its ingredients.\n* Pregnancy or nursing woman","ALL","18 Years",{"count":20,"type":21},13,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a 4-week comparison study between the intervention and control sides of the face. Purposive sampling to recruit 13 patients with seborrheic dermatitis will be conducted in this study. The study will start after researcher has been granted the Ethic Committee Approval. The process of subject recruitment and clinical data collection will take place at the Outpatient Department (OPD) while photograph taking and skin measurement will take place at Laser Center and Bioengineering Department, respectively. All bioengineering instruments will be operated under the climate controlled environment; i.e, at temperature 20+\u002F-2 degree Celsius and 50+\u002F-2 % of relative humidity. A subject must get acclimatized to the ambient atmosphere for at least 30 minutes. The clinical data, skin barrier function, the quality of life, subject's satisfaction scale will be collected at the first day (D0, as baseline) and 4th week after finishing the test product (Wk4).",[27],"Seborrheic Dermatitis on the Face",[29,30,31,32,33,34],"seborrheic dermatitis","SEDASI score","antioxidant","skin hydration","split-face randomized controlled trial","Transepidermal water loss","RECRUITING","2026-06-08",{"date":38,"type":39},"2026-06-10","ACTUAL",{"date":41,"type":39},"2026-03-06",{"date":43,"type":21},"2026-07-01",{"name":45,"class":46},"Institute of Dermatology, Thailand","OTHER_GOV",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":5},"100634162","veneze-peptide-factor-hair-serum-compared-with-topical-2-minoxidil-for-androgenetic-alopecia-100634162","NCT07536100","VENEZE Peptide Factor Hair Serum Compared With Topical 2% Minoxidil for Androgenetic Alopecia","Effectiveness and Tolerability of VENEZE Peptide Factor Hair Serum for Pattern Hair Loss: A Randomized Double-blind Study","VENEZE-AGA","Inclusion Criteria:\n\n* Male or female participants aged ≥18 years.\n* Diagnosed with androgenetic alopecia (AGA): Norwood-Hamilton classification III-V in males or Ludwig classification I-II in females.\n* Able to read and write for completion of study questionnaires (e.g., Patient Global Assessment, Hair Growth Questionnaire).\n* Willing to comply with study procedures, including maintaining consistent hair color and hairstyle throughout the study.\n* Hair length in the non-balding area (vertex surrounding area) ≥2 cm at each visit.\n* Able to attend all scheduled visits during the 24-week study period.\n\nExclusion Criteria:\n\n* Presence of unstable or uncontrolled systemic diseases that may affect hair growth or loss within 6 months prior to screening (e.g., liver, renal, thyroid, cardiovascular, neurological diseases, diabetes, anemia).\n* History of malignancy within the past 5 years, except adequately treated basal cell carcinoma or squamous cell carcinoma.\n* Psychiatric disorders or other conditions that may affect participant safety or compliance.\n* Pregnant or breastfeeding women.\n\nHair and scalp-related exclusions:\n\n* Diffuse hair thinning involving the occipital area.\n* Scalp conditions or diseases affecting hair growth (e.g., tinea infection, non-AGA hair loss, psoriasis, uncontrolled seborrheic dermatitis).\n* History of hair transplantation at any time or hair extensions within 6 months prior to screening.\n* Use of cosmetic products for hair loss concealment within 2 weeks prior to screening.\n* Use of light\u002Flaser therapy on the scalp within 3 months prior to screening.\n* Use of supplements related to hair growth (e.g., zinc, biotin) within 3 months prior to screening.\n* Use of hair products containing active ingredients (e.g., caffeine, peptides) within 3 months prior to screening.\n* Hair procedures such as mesotherapy or stem cell injection within 3 months prior to screening.\n\nMedication-related exclusions:\n\n* Known hypersensitivity to study-related products or ingredients.\n* Use of dutasteride within 12 months prior to screening.\n* Use of systemic cytotoxic agents.\n* Use of systemic glucocorticoids within 3 months prior to screening (except inhaled or topical corticosteroids not applied to the scalp).\n* Use within 6 months prior to screening of:\n\n  * Minoxidil (topical or oral)\n  * Finasteride (topical or oral)\n  * Anti-androgenic drugs (e.g., spironolactone, cyproterone acetate, flutamide, bicalutamide)\n  * Prostaglandin analogs applied to the scalp\n  * Estrogen or progesterone topical preparations\n  * Tamoxifen\n  * Drugs associated with hypertrichosis (e.g., cyclosporine, phenytoin)\n  * Drugs associated with hair loss (e.g., valproic acid)\n* Participation in another clinical trial within 1 month prior to screening or during this study.",{"count":57,"type":21},80,[24],"This study aims to evaluate the effectiveness and tolerability of a peptide-based hair serum compared with topical minoxidil in patients with androgenetic alopecia. Participants will be randomly assigned, in a double-blind manner, to receive either the peptide hair serum or topical minoxidil. The primary objective is to assess improvement in hair growth over the study period, including changes in hair density and hair thickness. Secondary outcomes will include safety and tolerability assessments. The findings of this study may provide evidence supporting an alternative treatment option for patients with androgenetic alopecia.",[61],"Androgenetic Alopecia (AGA)",[63,64,65],"Androgenetic alopecia","Peptide hair serum","Minoxidil","2026-05-09",{"date":68,"type":39},"2026-05-13",{"date":70,"type":39},"2026-05-05",{"date":72,"type":21},"2026-11-30",{"name":45,"class":46},""]